
About PeptiMimesis
PeptiMimesis is a Healthcare company based in Illkirch-graffenstaden (France) founded in 2015. Transmembrane therapeutic peptides are developed for oncology and immune diseases. PeptiMimesis has raised $2.14 million across 2 funding rounds from investors including Capital Grand Est. PeptiMimesis offers products and services including Therapeutic Peptides. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
PeptiMimesis was founded in 2015 and is based in Illkirch Graffenstaden, France. Focus is placed on developing transmembrane therapeutic peptides targeting oncology and immune diseases. Internal assets are advanced to key value inflection points prior to out-licensing to pharmaceutical partners. Partnerships are sought with pharma and biotech entities using the companys unique technology platform.
- Headquarters Illkirch-graffenstaden, France
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website peptimimesis.com
- Total Equity Funding$2.14M (USD)
in 2 rounds
- Latest Funding Round$740K (USD), Seed
Mar 2017
- Investors
Products & Services of PeptiMimesis
PeptiMimesis offers a comprehensive portfolio of products and services, including Therapeutic Peptides.
Peptides that interfere with receptor dimerization for oncology treatment
Funding Insights of PeptiMimesis
PeptiMimesis has successfully raised a total of $2.14M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $740 thousand completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.14M
- Total Rounds 2
- Last Round Seed β $740,000
- First Round $1.4M
(Apr 2016)
- Investors Count 1
All 2 funding rounds of PeptiMimesis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2017 | $740,000 | Seed | β | β | |
| Apr 2016 | $1.4M | Seed | β | β |
1 investors in total: 1 institutional.
Investors in PeptiMimesis
PeptiMimesis has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Capital Grand Est.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment support is provided to businesses in Grand Est region. | capitalgrandest.eu | Schiltigheim, France |
Investor details for PeptiMimesis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PeptiMimesis
1 people are tracked at PeptiMimesis (1 in leadership).
| Name | Role | Group |
|---|---|---|
Marjorie Sidhoum | Chief Executive Officer | Leadership |
Complete people profiles for PeptiMimesis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PeptiMimesis
3 dated milestones of PeptiMimesis across 2 years, from founding to its latest funding, stage changes and deals.
- Founded PeptiMimesis is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Seed, of $740K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PeptiMimesis
PeptiMimesis was founded in 2015 and raised its 1st funding round 1 year after it was founded.
PeptiMimesis is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.
PeptiMimesis is a funded company, having raised a total of $2.14M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.4M, raised on Apr 2016.
PeptiMimesis was founded in 2015 and is based in Illkirch Graffenstaden, France. Focus is placed on developing transmembrane therapeutic peptides targeting oncology and immune diseases. Internal assets are advanced to key value inflection points prior to out-licensing to pharmaceutical partners. Partnerships are sought with pharma and biotech entities using the companys unique technology platform.
PeptiMimesis offers Therapeutic Peptides.
PeptiMimesis has 1 investor. Key investors include Capital Grand Est.